MID-VOLUME · FEMALE-LED
oxybutynin Side Effects
oxybutynin (also sold as Ditropan) sits MID-VOLUME #198 of 524 by FAERS report count. Lead signal: FEMALE-LED - 78% of sex-coded reports are female (20,928 F / 5,943 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 28,434
- FAERS reports
FDA Adverse Event Reporting System extract for oxybutynin. Stamp set CASELOAD · DEATH-HEAVY · HOSP-MID. How figures are compiled.
oxybutynin reporting skew - 78% of sex-coded reports are female (20,928 F / 5,943 M). Volume band MID-VOLUME #198 of 524 by FAERS report count; caseload CASELOAD.
Mid-book FAERS page for oxybutynin (Ditropan) (28,434 reports). Signature FEMALE-LED. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2003–2025). Stamps CASELOAD · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
FATIGUE leads 1,539 of 28,434 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (78% of sex-coded rows)
Age peak 45-64 (5,978 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (1,650 reports, 5.8%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 680 |
| COMPLETED SUICIDE | 193 |
| TOXICITY TO VARIOUS AGENTS | 89 |
| PNEUMONIA | 73 |
| CARDIAC ARREST | 69 |
| FALL | 64 |
| RENAL FAILURE | 63 |
| RESPIRATORY FAILURE | 63 |
| MYOCARDIAL INFARCTION | 59 |
| DYSPNOEA | 57 |
| ASTHENIA | 56 |
| SEPSIS | 56 |
| DIARRHOEA | 49 |
| PAIN | 49 |
| ACUTE KIDNEY INJURY | 48 |
| CHRONIC KIDNEY DISEASE | 47 |
| FATIGUE | 46 |
| URINARY TRACT INFECTION | 46 |
| CARDIO-RESPIRATORY ARREST | 43 |
Reactions in Hospitalization Reports
Hospitalization mid-share (6,729, 23.7%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| FALL | 746 |
| URINARY TRACT INFECTION | 600 |
| PNEUMONIA | 451 |
| ASTHENIA | 426 |
| NAUSEA | 395 |
| FATIGUE | 394 |
| PAIN | 391 |
| DIARRHOEA | 353 |
| DYSPNOEA | 342 |
| VOMITING | 336 |
| DIZZINESS | 333 |
| PYREXIA | 290 |
| MALAISE | 284 |
| CONFUSIONAL STATE | 279 |
| HEADACHE | 277 |
| WEIGHT DECREASED | 274 |
| ACUTE KIDNEY INJURY | 247 |
| ANAEMIA | 237 |
How to read oxybutynin FAERS figures (CASELOAD · DEATH-HEAVY · HOSP-MID)
FAERS holds 28,434 voluntary reports linked to oxybutynin (Ditropan), 2003-2025. Death is listed on 1,650 (5.8%). Hospitalization appears on 6,729 (23.7%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-HEAVY · HOSP-MID as signal-detection rates next to 78% of sex-coded reports are female (20,928 F / 5,943 M).
Read with oxybutynin
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 28,498 FAERS cases (Δ 64 heavier vs oxybutynin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 28,502 FAERS cases (Δ 68 heavier vs oxybutynin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 28,128 FAERS cases (Δ 306 lighter vs oxybutynin); DEATH-MARKED · HOSP-MID · FEMALE-LED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 28,005 FAERS cases (Δ 429 lighter vs oxybutynin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 56.3 pp vs oxybutynin's DEATH-HEAVY): CASELOAD · HOSP-MID.
oxybutynin stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload CASELOAD and the label guide.